 |
 |
 |
Home |
| Dr. Graham Fagg Partner, Seroba Kernel |
 |
| Dr. Graham Fagg is a Partner of Seroba Kernel Life Sciences Limited and a Partner at Rosetta Capital (London). Graham has been working with Seroba since 2003. At Rosetta, Graham sits on the Boards of PainCeptor (Canada) and Aditech (Sweden) and manages portfolio investments in Novagali (France) and Curalogic (Denmark). Graham has extensive management experience in pharmaceutical R&D and the investment sectors, having held senior roles at Ciba (now Novartis, Basel) in drug discovery, business development, corporate venturing, research planning and partnership management, and subsequently at Catalyst BioMedica, a subsidiary of the Wellcome Trust (London), where he was founding Managing Director. Prior to Rosetta, his investment experience includes periods at Accel Partners (San Francisco), where he was involved in the initial financing of Idun Pharmaceuticals, and at Catalyst (London), which invested in a wide range of pre-seed and start-up opportunities in the medical sciences sector including companies such as Cardiodigital, DanioLabs, Molecular Skincare and Paradigm Therapeutics. Graham received a PhD from University College London in 1976. |
|
Kernel Management Partners Limited, trading as Kernel Capital, is regulated by the Central Bank of Ireland. |